Skip to main content
. 2023 Jan 4;37(1):71–91. doi: 10.1007/s40290-022-00452-w

Fig. 4.

Fig. 4

Proposed risk-based assessment end-to-end registration process in the Pharmaceutical Evaluation Management, Pharmaceutical and Analytical Pre-Registration Unit for quality and bioequivalence assessments. The process is repeated for the response cycle and only 10 working days are allocated for the second response cycle. HPA Health Products Authorisation, PC Portfolio Coordinator